Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML2917

Sigma-Aldrich

BAY 36-7620

≥98% (HPLC)

Synonym(s):

(3aS,6aS)-5-Methylene-6a-(naphthalen-2-ylmethyl)hexahydro-1H-cyclopenta[c]furan-1-one, (3aS,6aS)-6a-Naphtalen-2-ylmethyl-5-methyliden-hexahydro-cyclopenta[c]furan-1-one, (3aS,6aS)-Hexahydro-5-methylene-6a-(2-naphthalenylmethyl)-1H-cyclopenta[c]furan-1-one, BAY36-7620

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C19H18O2
CAS Number:
232605-26-4
Molecular Weight:
278.35
MDL number:
MFCD03700725
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -43 to -35°, c = 0.5 in chloroform-d

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

C=C1C[C@@](CC2=CC3=C(C=C2)C=CC=C3)(C(OC4)=O)[C@]4([H])C1

InChI

1S/C19H18O2/c1-13-8-17-12-21-18(20)19(17,10-13)11-14-6-7-15-4-2-3-5-16(15)9-14/h2-7,9,17H,1,8,10-12H2/t17-,19+/m1/s1

InChI key

CVIRWLJKDBYYOG-MJGOQNOKSA-N

Biochem/physiol Actions

BAY36-7620 is a non-competitive, potent and selective metabotropic glutamate mGlu1 receptor (mGluR1) antagonist (IC50 = 160 nM against 0.1 μM (EC50) Glu-stimulated IP) with inverse agonist activity (IC50 = 380 nM with 36-44% basal IP inhibition at 10 μM). BAY36-7620 exhibits neuroprotective (0.01 and 0.03 mg/kg/h, iv. infusion during 4h post acute subdural hematoma induction in rats; triple 0.03-3 mg/kg bolus iv. 0, 2 & 4 h post middle cerebral artery occlusion in rats) and anticonvulsive (MED = 10 mg/kg, iv. immediately after pentylenetetrazole-induced convulsions in mice) efficacy in vivo.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

J De Vry et al.
European journal of pharmacology, 428(2), 203-214 (2001-10-25)
This study characterized the neuroprotective and behavioral effects of (3aS,6aS)-6a-naphtalen-2-ylmethyl-5-methyliden-hexahydro-cyclopenta[c]furan-1-on (BAY 36-7620), a novel, selective and systemically active metabotropic glutamate (mGlu)(1) receptor antagonist. In the rat, neuroprotective effects were obtained in the acute subdural hematoma model (efficacy of 40-50% at
U H Schröder et al.
Neuroscience, 157(2), 385-395 (2008-10-04)
In this study we evaluated the effects of the novel, potent non-competitive metabotropic glutamate receptor (mGluR) 1 antagonist (3aS,6aS)-6a-naphthalen-2-ylmethyl-5-methyliden-hexahydro-cyclopental[c]furan-1-on (BAY 36-7620) on different types of synaptic plasticity in the hippocampal cornu ammonis (CA) 1-region and on hippocampus-dependent spatial learning. After
Lauren M Watson et al.
American journal of human genetics, 101(3), 451-458 (2017-09-09)
The metabotropic glutamate receptor 1 (mGluR1) is abundantly expressed in the mammalian central nervous system, where it regulates intracellular calcium homeostasis in response to excitatory signaling. Here, we describe heterozygous dominant mutations in GRM1, which encodes mGluR1, that are associated
Hyun Geun Shim et al.
Journal of neurophysiology, 115(5), 2446-2455 (2016-02-26)
Homeostatic intrinsic plasticity is a cellular mechanism for maintaining a stable neuronal activity level in response to developmental or activity-dependent changes. Type 1 metabotropic glutamate receptor (mGlu1 receptor) has been widely known to monitor neuronal activity, which plays a role
Rachel E Sexton et al.
Scientific reports, 8(1), 16008-16008 (2018-10-31)
Breast cancer remains a major cause of death among women. 15% of these cancers are triple negative breast cancer (TNBC), an aggressive subtype of breast cancer for which no current effective targeted therapy exists. We have previously demonstrated a role
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service